Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF DECEMBER 10, 2022 SAM #7680
SPECIAL NOTICE

Q -- Cytopathology & Thyrosequence Testing Service

Notice Date
12/8/2022 8:58:53 AM
 
Notice Type
Special Notice
 
NAICS
621511 — Medical Laboratories
 
Contracting Office
242-NETWORK CONTRACT OFFICE 02 (36C242) ALBANY NY 12208 USA
 
ZIP Code
12208
 
Solicitation Number
36C24223Q0167
 
Archive Date
01/07/2023
 
Point of Contact
Safa Shleiwet, Contracting Officer, Phone: (718) 741-4766
 
E-Mail Address
safa.shleiwet@va.gov
(safa.shleiwet@va.gov)
 
Awardee
null
 
Description
NOTICE OF INTENT. The Department of Veterans Affairs, Network Contracting Office 2 intends to solicit and award a sole-source, firm-fixed-price, Indefinite Delivery Contract (with individual task orders issued for the annual ordering periods) with Cytopath Biopsy Lab, Inc. (760 Westchester Ave., Rye Brook, NY 10573-1341) in accordance with 41 U.S.C. § 1901, as implemented by FAR 13.106(b)(2)(i): Only one responsible source and no other supplies or services will satisfy agency requirements. The contract anticipated effective date is January 3, 2023, for one year with four option years. This contract is for Cytopathology & Thyrosequence Testing Service. Contractor shall provide for the New York Harbor Healthcare System at Brooklyn VA Medical Center, 800 Poly place, Brooklyn NY, 11209 approximately 180 tests per year. Patient samples obtained through fine needle aspirate (FNA) biopsies are collected for both cytopathology assessment and ThyroSeq® GC. Initially cytopathology assessment is conducted. If the sample is read out as benign, or non-diagnostic, the sample is not sent out for genetic analysis, however if it is read as Bethesda III, IV, or V, ThyroSeq® GC Next Generation gene sequencing is performed. ThyroSeq® Genomic Classifier (GC) test utilizes next-generation sequencing to analyze DNA and RNA of 112 thyroid-related genes for four main classes of molecular alterations, including mutations, gene fusions, copy number alterations, and gene expression alterations. The results are processed by a unique Genomic Classifier (GC) and reported as Positive or Negative. As we move forward with targeted therapies, samples which are Bethesda VI (papillary carcinoma), or other thyroid cancers will also be sent for further testing. The NAICS code is 621511 (Medical Laboratories) with a small business size standard of $36.5 Million. This is for informational purposes only and is not construed as a commitment by the Government. This is not a request for offers. A determination by the Government not to compete this procurement based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurements for this item. Point of Contact is Safa Shleiwet, Contracting Officer at safa.shleiwet@va.gov
 
Web Link
SAM.gov Permalink
(https://sam.gov/opp/15d79abde0184f0b8706e8dcfa1dab9f/view)
 
Record
SN06538486-F 20221210/221208230059 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.